表皮生长因子受体酪氨酸激酶抑制剂新辅助治疗非小细胞肺癌。
Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer.
机构信息
Department of Medicine, University of California Irvine Medical Center, Orange CA, USA.
Department of Medicine, University of California Irvine Medical Center, Orange CA, USA; Division of Hematology and Oncology, Department of Medicine, University of California Irvine Medical Center, Orange CA, USA.
出版信息
Cancer Treat Rev. 2024 May;126:102724. doi: 10.1016/j.ctrv.2024.102724. Epub 2024 Mar 27.
Non-small cell lung cancer (NSCLC) stages I-III are predominantly treated with surgery and combination immunotherapy and chemotherapy. A majority of these studies excluded patients with EGFR and ALK alterations. There are several completed and ongoing trials evaluating neoadjuvant treatment with EGFR-TKI monotherapy, combination therapy with chemotherapy, and combination therapy with immunotherapy. Here, we review completed clinical trials and discuss current ongoing trials' potential benefits, challenges, and future directions in the field.
非小细胞肺癌（NSCLC）I-III 期主要采用手术和联合免疫治疗及化疗。这些研究大多排除了 EGFR 和 ALK 改变的患者。目前有几项已完成和正在进行的试验评估了 EGFR-TKI 单药、联合化疗和联合免疫治疗的新辅助治疗。在此，我们回顾了已完成的临床试验，并讨论了当前正在进行的试验在该领域的潜在益处、挑战和未来方向。
Zotero 插件